Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: EyeDrMike who wrote (2586)	11/18/1997 10:04:00 AM
From: Cacaito	Respond to of 23519

I doubt Asencio will go after Pfizer, they are a solid company and they will do well even if one product failed. Asencio like the Solv-Exs and Bre-Xs of the world, start ups with dubious products and huge market values.

To: EyeDrMike who wrote (2586)	11/18/1997 1:48:00 PM
From: Bull-like	Respond to of 23519

Please, let's not push the envelope. Viagara is a totally different story. Let's not get over-excited. Da bull

To: EyeDrMike who wrote (2586)	11/18/1997 8:46:00 PM
From: BigKNY3	Read Replies (3) \| Respond to of 23519

Eye <<Is Viagra next??>> I would like some insight on why you asked this question. Here's some questions for you to ponder: 1. Have you ever heard of Asensio before today? 2. Do you believe every PR or news item that you read? 3. Do you know the position of Asensio and possible biases behind their press release? 4. Do you think that Zonagen R&D is equivalent to Pfizer's R&D? 5. Do you really think that Pfizer has sent Viagra clinical data that is "fundamentally flawed in design and execution." 6. Would it be smarter for VVUS to take advantage of the expansion of the ED market, promote the benefits and differences of MUSE, and not look under rocks to keep the oral ED agents off the market. Eye, "I" look forward to your response. BigKNY3